Implant Sciences Ships Portable, Hand-held Quantum Sniffer Units on Time and On Schedule
Implant Sciences announced the on-time shipment on September 30, 2004 of three (3) production units of the Quantum Sniffer explosives detection device to a military agency in accordance with the terms of a certain contract awarded to the Company in October 2003.
WAKEFIELD, MA (PRWEB) October 1, 2004 -- Implant Sciences Corporation (AMEX:
"IMX", "IMX.WS") a developer and manufacturer of products for national security,
medicine and industry, announced the on-time shipment on September 30, 2004 of
three (3) production units of the Quantum Sniffer explosives detection device to
a military agency in accordance with the terms of a certain contract awarded to
the Company in October 2003.
The Quantum Sniffer is the Company's trace
explosives detection device using the Company's patented, proprietary QSTM Ion
Mobility Spectrometry technology, which electronically detects minute quantities
of explosive vapor molecules in the air. These units may be used to determine
the presence of, or confirm the absence of, common explosives in personal
equipment, packages, postal mail and cargo that may be conveyed by persons,
vehicles, airplanes, and watercraft.
Dr. Anthony J. Armini, PhD., CEO of
Implant Sciences, commented, “This shipment of production-ready explosives
detection equipment represents the culmination of several years of research,
development and commercialization of our unique explosives detection technology.
We believe the Quantum Sniffer could have a significant impact in effectively
detecting trace amounts of explosives on personnel and vehicles. The Quantum
Sniffer represents the first of many devices using our QSTM Ion Mobility
Spectrometry technology that could be used as an effective tool in the war on
terrorism.”
Dr. Armini further commented, “Given the sensitive nature of
our explosive detection contracts with government and military agencies, we are
specifically prohibited from divulging any information to the public without the
prior approval of the contracting agent. As the QSTM units shipping yesterday
were evaluated, and subject to the requirements of confidentiality mandated by
certain government and military agencies with whom we contract, we will provide
further details as to the progress of the evaluations of our explosives
detection devices. However, we believe that with this timely delivery of our
commercially available QSTM explosives detection device, we are now in a
position to exploit the distribution channels we have already established, and
to add to our distribution channels, in order to actively seek orders from
governmental agencies, the military sector, and companies in the private sector,
both domestically and internationally.”
The Company will be updating its
corporate website at www.implantsciences.com as soon as possible to include
photographs of the new portable, hand-held QSTM explosives detection devices and
their shipping containers.
Company Conference Call
Management will
host a conference call on Tuesday, October 5, 2004 at 4:10 PM Eastern Time to
review the financial results and other corporate events, including the status of
our explosives detection activities, followed by a Q&A session. The call can
be accessed by dialing: 888-396-2384 and entering the passcode: 75716612.
Participants are asked to call the assigned number approximately 5 minutes
before the conference call begins. A replay of the conference call will be
available two hours after the call for the following two business days by
dialing: 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and
entering passcode: 22335660.
This call is being webcast by CCBN and can
be accessed at Implant Sciences website at www.implantsciences.com.
The webcast can also be accessed at www.runonideas.com. The
webcast is also being distributed over CCBN’s Investor Distribution Network to
both institutional and individual investors. Individual investors can listen to
the call through CCBN’s individual investor center at www.fulldisclosure.com or
by visiting any of the investor sites in CCBN’s Individual Investor Network.
Institutional investors can access the call via StreetEvents, CCBN’s
password-protected event management site, at www.streetevents.com.
About Implant Sciences
Implant Sciences, incorporated in 1984, is
using its core ion technology to develop, manufacture and market products for
national security, medicine, and industry. Under development are portable and
bench-top trace element detection devices to identify explosives, narcotics and
other toxic materials. The Company has also received government grants from the
US Army, Navy and Air Force, and the Transportation Security Administration to
adapt the Company's explosive detection technology to a wide number of security
requirements.
Using its proprietary ion implantation and thin film
coating technologies, Implant Sciences has a sophisticated production line that
modifies the surface characteristics of orthopedic joint implants to reduce
polyethylene wear, thereby substantially increasing the life of the implants.
The Company also manufactures and markets radioactive and non-radioactive
products for medical use, including radioactive seeds for treating prostate
cancer that are distributed throughout the United States by its own direct sales
force. In parallel with the production of these seeds, it is also developing
additional brachytherapy products for the treatment of breast, eye, and other
cancers.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect," “should,” or similar expressions. These
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements inherently
involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, continued
acceptance of the Company's products and services in the marketplace, the
ability of the Company to develop effective new products and receive
governmental approvals of such products, competitive factors, dependence upon
third-party vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
# #
#
Source : http://www.prweb.com/releases/2004/10/prweb163698.htm